University Medicine Zurich (UMZH) supports the expansion of regulatory expertise in the field of innovative medicines at ZH3D
On August 26, 2025, the UMZH Coordination Committee approved the application to fund a specialist in the regulatory field of Good Manufacturing Practice (GMP) for innovative medicines at ZH3D.
The UMZH network is entering a new era of personalized medicine with increasingly complex therapeutic approaches. New developments such as biologics, advanced therapy medicinal products, cell and gene therapies, and innovative microbiome therapies require specialized regulatory expertise.
A concrete example of the urgent need is the current development of fecal microbiota transplantation (FMT) according to GMP standards. This innovative, state-of-the-art microbiome therapy is currently being implemented with ZüriPharm AG and will be available to all UMZH clinics. This therapy opens up promising new treatment options for antibiotic-resistant infections, ulcerative colitis, immunotherapy-resistant cancer, acute coronary syndrome, depression, and graft-versus-host disease.
The FMT project is an advanced pilot project that exemplifies the implementation of regulatory processes. These and future applications require the recruitment of a specialized GMP regulatory expert and the ability to call on external experts when needed. The investment not only strengthens ZH3D, but also Zurich's position in the field of personalized medicine, promotes synergies with existing initiatives, and creates potential for intellectual property, spin-offs, and partnerships.